Barclays Reaffirms Hold Rating for Charles River Laboratories Intl. (NYSE:CRL)

Barclays restated their hold rating on shares of Charles River Laboratories Intl. (NYSE:CRL) in a report released on Friday, February 16th. The firm currently has a $110.00 price objective on the medical research company’s stock.

Other analysts also recently issued research reports about the company. TheStreet downgraded Charles River Laboratories Intl. from an a- rating to a c+ rating in a research note on Tuesday, February 13th. JPMorgan Chase & Co. boosted their target price on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an overweight rating in a research report on Wednesday, February 14th. SunTrust Banks downgraded Charles River Laboratories Intl. from a buy rating to a hold rating and boosted their target price for the company from $107.89 to $111.00 in a research report on Monday, January 22nd. They noted that the move was a valuation call. Evercore ISI initiated coverage on Charles River Laboratories Intl. in a report on Thursday, January 18th. They set an in-line rating and a $117.00 price objective for the company. Finally, Argus initiated coverage on Charles River Laboratories Intl. in a report on Wednesday, December 13th. They set a buy rating and a $120.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Charles River Laboratories Intl. presently has an average rating of Buy and a consensus target price of $116.85.

Charles River Laboratories Intl. (NYSE:CRL) traded down $1.48 during midday trading on Friday, reaching $112.71. The company had a trading volume of 316,950 shares, compared to its average volume of 510,893. The company has a market cap of $5,350.00, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 1.61 and a beta of 0.71. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.54. Charles River Laboratories Intl. has a 52 week low of $86.44 and a 52 week high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.14. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The company had revenue of $478.50 million for the quarter, compared to the consensus estimate of $475.02 million. During the same quarter last year, the company earned $1.21 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. equities research analysts anticipate that Charles River Laboratories Intl. will post 5.77 EPS for the current year.

In other news, Director Online Communications Bdirect sold 131,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $0.29, for a total value of $37,990.00. Also, CEO James C. Foster sold 4,800 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $106.69, for a total value of $512,112.00. Following the completion of the sale, the chief executive officer now owns 306,914 shares in the company, valued at approximately $32,744,654.66. The disclosure for this sale can be found here. Insiders sold 207,720 shares of company stock worth $8,455,637 over the last three months. Corporate insiders own 2.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in Charles River Laboratories Intl. by 0.8% during the fourth quarter. BlackRock Inc. now owns 4,034,318 shares of the medical research company’s stock worth $441,557,000 after purchasing an additional 31,676 shares in the last quarter. William Blair Investment Management LLC boosted its position in Charles River Laboratories Intl. by 3,017.9% during the fourth quarter. William Blair Investment Management LLC now owns 1,406,744 shares of the medical research company’s stock worth $153,968,000 after purchasing an additional 1,361,626 shares in the last quarter. Renaissance Technologies LLC boosted its position in Charles River Laboratories Intl. by 4.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,398,700 shares of the medical research company’s stock worth $153,088,000 after purchasing an additional 58,991 shares in the last quarter. State Street Corp boosted its position in Charles River Laboratories Intl. by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after purchasing an additional 28,365 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its position in Charles River Laboratories Intl. by 15.3% during the fourth quarter. Mackenzie Financial Corp now owns 1,071,178 shares of the medical research company’s stock worth $117,240,000 after purchasing an additional 142,382 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Barclays Reaffirms Hold Rating for Charles River Laboratories Intl. (NYSE:CRL)” was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/14/charles-river-laboratories-intl-s-crl-hold-rating-reaffirmed-at-barclays/1890425.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.